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Background. Plasmodium vivax malaria commonly follows treatment of falciparum malaria in regions of co-
endemicity. This is an important cause of preventable morbidity.
Methods. We examined the factors contributing to the risk of recurrence of P. vivax infection after treatment of
acute falciparum malaria in a series of clinical trials conducted on the Thai-Myanmar border from 1991 through
2005.
Results. Overall, 10,549 patients (4960 children aged ,15 years and 5589 adults) were treated for falciparum
malaria; of these patients, 9385 (89.0%) had Plasmodium falciparum monoinfection and 1164 (11.0%) had mixed
P. falciparum/P. vivax infections according to microscopic examinations performed at screening. The cumulative
proportion of patients with P. falciparum infection recurrence by day 63 was 21.5% (95% conﬁdence interval [CI],
20.3%–22.8%), and the cumulative proportion with P. vivax infection recurrence was 31.5% (95% CI, 30.1%–
33.0%). Signiﬁcant risk factors for P. vivax infection recurrence were mixed infection at enrollment, male sex,
younger age, lower hematocrit, higher asexual P. falciparum parasite density (P , .001 for all factors), and
P. falciparum gametocytemia at enrollment (P 5 .001). By day 63, the cumulative risk of vivax malaria
after P. falciparum monoinfection was 51.1% (95% CI, 46.1%–56.2%) after treatment with rapidly eliminated
drugs (t1/2 ,1 day), 35.3% (95% CI, 31.8%–39.0%) after treatment with intermediate half-life drugs (t1/2 1–7 days),
and 19.6% (95% CI, 18.1%–21.3%) after treatment with slowly eliminated drugs (t1/2 . 7 days) (P , .001, by test
for trend). Artemisinin-based combinations containing meﬂoquine or piperaquine, compared with the artemether-
lumefantrine and artesunate-atovaquone-proguanil combinations, were associated with a 3.6-fold to 4.2-fold lower
adjusted hazard ratio for P. vivax infection recurrence within 63 days after pure or mixed P. falciparum infections
(P , .001, for comparisons with artesunate-meﬂoquine).
Conclusions. On the Thai-Myanmar border, P. vivax is the most common cause of parasitological failure after
treatmentforfalciparummalaria.SlowlyeliminatedantimalarialsreducetheriskofearlyP.vivax infectionrecurrence.
In Southeast Asia, the incidence of Plasmodium vivax
infection after treatment of falciparum malaria is sub-
stantially greater than would be expected on the basis of
entomological inoculation rates [1–7]. The reasons for
this are not clear. One postulate is that contemporane-
ous inoculation of P. vivax and Plasmodium falciparum
occurs relatively frequently and that acute P. falciparum
infection suppresses P. vivax parasitemia below levels
detectable by light microscopy [1, 8]. According to this
hypothesis, most recurrent P. vivax infections after
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simultaneously acquired hypnozoites [1, 8]. An alternative
theory is that either P. falciparum infection or its treatment
somehow precipitate blood-stage relapse from dormant, pre-
viously acquired hypnozoites [8].
Whatever the underlying mechanism, P. vivax infection re-
currence after falciparum malaria carries signiﬁcant morbidity,
impairs clinical and hematological recovery [3, 9], and worsens
the socioeconomic burden of malaria [10]. Because asexual
P. vivax parasitemia after blood-stage treatment is frequently
associated with concurrent gametocytemia [3, 9, 11], it is also
likely to have an important role in sustaining transmission of
P. vivax [12]. The efﬁcacy of antimalarial treatment for pre-
venting P. vivax infection recurrence is therefore an important
consideration for malaria control strategies.
We have used pooled data from a large series of clinical trials
conducted at Shoklo Malaria Research Unit on the Thai-
Myanmar border between 1991 and 2005 to establish the effect
of demographic and clinical factors as well as antimalarial
elimination kinetics on the risk of P. vivax infection recurrence
after P. falciparum or mixed P. vivax/P. falciparum malaria.
METHODS
Study Sites
The studies included in this analysis were performed from 1991
through 2005 at camps for displaced persons of the Karen ethnic
minority and border clinics that served mainly Karen and Bur-
mese migrant workers along the northwestern border of Thai-
land. In the mid-1990s, the local annual incidence of malaria was
approximately1episodeperperson-year,53%ofwhichweredue
to P. vivax, 37% of which were due to P. falciparum, and 10% of
which were due to mixed infection (determined according to the
results of examination with light microscopy) [13]. Virtually all
P. falciparum infections and 90% of P. vivax infections were
symptomatic [13]. Standard treatment of uncomplicated falci-
parum malaria was meﬂoquine monotherapy (25 mg base/kg
total dose) from 1991 through 1994 and was meﬂoquine (25 mg
base/kg) plus artesunate (12 mg/kg over 3 days) thereafter [14].
Design of the Studies
This analysis includes 24 studies that investigated 25 different
antimalarial treatment regimens. None included routine ad-
ministrationofprimaquine(Table1).Sixteenofthestudieswere
randomized controlled trials of different treatments for
uncomplicatedfalciparum malaria withor without concomitant
P. vivax infection; the remainder were single-arm clinical trials
conducted to assess drug efﬁcacy or safety. None included
children who weighed ,5 kg or pregnant women. Two studies
restricted recruitment to children <15 years of age, and 1 study
restricted recruitment to children ,5 years of age (Table 1).
Patients with severe disease according to World Health Or-
ganization criteria [15] were excluded, although the studies of
intravenousquinine plus meﬂoquine and of the 5-day and 7-day
courses of artesunate in combination with meﬂoquine included
patients with uncomplicated hyperparasitemia (.4% para-
sitisedredbloodcells)(Table1).Follow-upwasstandardizedfor
all studies and lasted 28 days (6 studies; 1398 patients), 42 days
(11 studies; 5354 patients), or 63 days (7 studies; 3797 patients).
Patients were seen every day until they were afebrile and had
experienced parasite clearance and were then seen weekly
thereafter. In the event of illness that occurred between these
visits, patients were asked to return to the clinic for treatment.
Fully informed consent was obtained before enrollment in all of
the studies. The studies were approved by the ethics committees
of the Faculty of Tropical Medicine, Mahidol University, and
Oxford University (OXTREC).
Study Data
Basic demographic and clinical details were recorded at enroll-
ment, including age, sex, parasitemia, temperature, and in most
cases,hematocritandwhitebloodcell(WBC)count.Symptoms,
temperature, and parasite count were assessed at follow-up
visits.DiagnosisofPlasmodiuminfectionandsubsequentspecies
identiﬁcation were established by examination of Giemsa-
stained thick and thin blood ﬁlms. Parasitemia was reported as
the number of asexual parasites per 500 WBCs or per 1000 red
blood cells and subsequently converted to a count per microliter
using the patient’s WBC count or hematocrit, if available.
Population means or assumed values of 8300 WBCs/lLa n d
35%, respectively, were used when necessary. Asexual parasite
densities in mixed infection were given as a summed total in the
majority of studies and were given separately for both species in
a minority. For this analysis, we used the summed total.
Patients were censored and deemed to have experienced
treatment failure if there were signs of early treatment failure
due to either malaria parasite species [16], if asexual P. falci-
parum or P. vivax parasitemia persisted beyond 7 days, or if
either species reappeared in the circulation up to 63 days after
initial clearance. Patients who did not experience failure were
censored on the date of their last negative blood smear result.
Statistical Analysis
The primaryoutcome for thisanalysis was recurrenceof P. vivax
infection up to 63 days after treatment for P. falciparum or
mixed P. falciparum/P. vivax infection. Potential risk factors
examined were species of infection at enrollment (P. falciparum
ormixedinfection),age,sex, initiallogeparasitedensity,baseline
hematocrit, and P. falciparum gametocytemia at enrollment (yes
or no). We compared nonparametric continuous data using the
Kruskal-Wallis test, unpaired proportions using the v
2 test, and
paired proportions using McNemar’s test. The impact of anti-
malarial drugs was assessed in 2 separate comparisons. First, we
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grouped by their terminal elimination half-lives (t1/2) (Table 1;
short was deﬁned as t1/2 , 1 day,intermediatewasdeﬁned as t1/2
. 1 day and , 1 week, and long was deﬁned as t1/2 . 1w e e k ) .
Second, we compared outcomes between individual artemisinin
combination therapies. The Kaplan–Meier function and log-
Table 1. Details of Treatment Regimens and Characteristics of Patients
Code
Total treatment
dose (total regimen
duration, total number
of doses) Year(s) studied t½
No. of
patients
Male
sex, no.
(%) of
patients
Age,
median
years
(90% range)
Parasitemia,
median parasites/lL
(90% range)
AAP Artesunate 12 mg/kg (3 days, 3 doses) 1
atovaquone 45 mg/kg (3 days, 3 doses) 1
proguanil 24 mg/kg (3 days, 3 doses)
1998–2000 Int 526 353 (67) 20 (7–41) 4408 (176–86,219)
AM7 Artemether 12 mg/kg (7 days, 7 doses) 1993–1996 Short 206 114 (55) 15 (2–33) 4850 (273–73,853)
AP Atovaquone 45 mg/kg (3 days, 3 doses) 1
proguanil 24 mg/kg (3 days, 3 doses)
1998–2000 Int 528 354 (67) 20 (7–43) 3841 (142–66,870)
AS3 Artesunate 12 mg/kg (3 days, 3 doses) 1992–1994 Short 5 3 (60) 14 (1–25) 105,278 (4428–151,926)
AS5 Artesunate 12 mg/kg (5 days, 5 doses) 1992–1995 Short 153 86 (56) 5 (1–25) 13,842 (424–430,713)
AS7 Artesunate 12 mg/kg (7 days, 7 doses) 1992–1996 Short 452 245 (54) 10 (2–29) 6972 (331–149,142)
AS7T7 Artesunate 12 mg/kg (7 days, 7 doses) 1
tetracycline 112 mg/kg (7 days, 7 doses)
1993–1995 Short 20 12 (60) 14 (9–39) 9396 (1065–205,230)
COA4 Artemether 6.8 mg/kg (3 days, 4 doses) 1
lumefantrine 48 mg/kg (3 days, 4 doses)
1995–1997 Int 387 265 (68) 21 (9–41) 4529 (278–88,957)
COA6a Artemether 10.2 mg/kg (60 h, 6 doses) 1
lumefantrine 72 mg/kg (96 h, 6 doses)
1996–1998
2000–2002
Int 1115 757 (68) 20 (7–45) 6414 (489–88,297)
COA6b Artemether 10.2 mg/kg (96 h, 6 doses) 1
lumefantrine 72 mg/kg (96 h, 6 doses)
1996–1997 Int 87 62 (71) 22 (11–41) 5460 (1023–78,561)
DP1 DHA 6.3 mg/kg (3 days, 4 doses) 1
piperaquine 51.3 mg/kg (3 days, 4 doses) 1
either artesunate 400 mg (3 days, 4 doses)
or extra DHA to achieve total dose of
12 mg/kg (3 days, 4 doses)
2002–2003 Long 174 125 (72) 20 (6–45) 16,830 (415–105,630)
DP3 DHA 6.3 mg/kg (3 days, 3 doses) 1
piperaquine 51.3 mg/kg (3 days, 3 doses)
2003–2004 Long 170 104 (61) 21 (6–43) 11,304 (496–75,360)
DP4 DHA 6.3 mg/kg (3 days, 4 doses) 1
piperaquine 51.3 mg/kg (3 days, 4 doses)
2002–2004 Long 340 216 (64) 22 (7–44) 13,816 (802–94,878)
M25 Meﬂoquine 25 mg/kg (1–2 days, 1–2 doses) 1991–1994 Long 949 543 (57) 14 (4–38) 3818 (213–36,754)
MA Artesunate 10 mg/kg (1 day, 3 doses) 1
meﬂoquine 15 mg/kg (1 day, 1 dose)
1991 Long 323 190 (59) 15 (3–38) 3486 (249–23,652)
MAM1 Artemether 4–10 mg/kg (1 day, 2–3 doses) 1
meﬂoquine 25 mg/kg (1 day, 1 dose)
1992 Long 19 10 (53) 20 (11–50) 6739 (253–228,592)
MAM3 Artemether 12 mg/kg (3 days, 3 doses) 1
meﬂoquine 25 mg/kg (1 day>, 1 dose)
1993–1994 Long 180 86 (48) 16 (5–42) 5299 (326–78,442)
MAS1 Artesunate 4 mg/kg (1 day, 1 dose) 1
meﬂoquine 25 mg/kg (1 day, 1 dose)
1992 Long 152 94 (62) 16 (4–35) 4847 (315–26,892)
MAS3 Artesunate 12 mg/kg (3 days, 3 doses) 1
meﬂoquine 25 mg/kg (1–2 days in 1–2 doses)
1992–2005 Long 4106 2,533 (62) 14 (5–39) 7300 (349–93,085)
MAS5 Artesunate 12 mg/kg (5 days, 5 doses) 1
meﬂoquine 25 mg/kg (1 day, 1 dose)
1992–1995 Long 57 29 (51) 6 (2–23) 326,874 (14,472–707,962)
MAS7 Artesunate 12 mg/kg (7 days, 7 doses) 1
meﬂoquine 25 mg/kg (1 day, 1 dose)
1993–1995 Long 139 82 (59) 7 (3–12) 270,957 (162,778–597,555)
MASF Artesunate 12 mg/kg (3 days, 3 doses) 1
meﬂoquine 25 mg/kg (3 days, 3 doses) in
ﬁxed combination
2004–2005 Long 247 170 (69) 20 (6–45) 14,469 (342–92,547)
MQIV Quinine 40 mg/kg (1 day, 3 doses) 1
meﬂoquine 25 mg/kg (1 day, 1 dose)
1993 Long 31 18 (58) 9 (4–29) 309,177 (150,850–562,186)
Q7 Quinine 210 mg/kg (7 days, 7 doses) 1992–1993 Short 28 16 (57) 5 (2–8) 3819 (130–26,158)
Q7T7 Quinine 210 mg/kg (7 days, 7 doses) 1
tetracycline 112 mg/kg (7 days, 7 doses)
1992–1994 Short 155 97 (63) 15 (9–34) 4284 (294–79,409)
Total 1991–2005 10,549 6,564 (62) 15 (5–40) 6586 (328–101,284)
NOTE. DHA, dihydroartemisinin; int, intermediate; t½, elimination half-life category.
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analyses were done using the Cox proportional hazards model
with gamma frailty to account for heterogeneity of results be-
tweenstudies[17](examinedusingtheWaldtestforsigniﬁcance
of interaction terms in preliminary models). Fulﬁllment of the
proportional hazards assumption was assessed using log-log
plots for each of the model covariables. All analyses were done
using Stata software, version 10.1 (Stata Corporation).
RESULTS
From 1991 through 2005, 10,549 patients (4960 children aged
,15 years and 5589 adults) were treated for falciparum malaria,
of whom 9385 (89.0%) had P. falciparum monoinfections and
1164 (11.0%) had mixed infections. Overall, 2925 patients
(27.7%) had recurrence of parasitaemia, 1570 (53.7%) with
monoinfection due to P. vivax alone, 1269 (43.4%) with mon-
oinfection due to P. falciparum alone, and 86 (2.9%) with mixed
infections. The median time to recurrence was 28 days for those
with P. falciparum monoinfection, 35 days for those with
P. vivax monoinfection, and 33 days for those with mixed in-
fection (P , .001 for overall difference). The number and
characteristics of individuals receiving each of the treatment
regimens are shown in Table 1. According to Kaplan–Meier
analyses, the cumulative proportion of patients experiencing
treatment failure due to any species by day 63 was 45.6% (95%
conﬁdence interval [CI], 44.1%–47.0%), the proportion expe-
riencing treatment failure due to P. falciparum infection (either
monoinfection or mixed infection) was 21.5% (95% CI, 20.3%–
22.8%) and due to P. vivax (either monoinfection or mixed
infection)was31.5%(95%CI,30.1%–33.0%).Overall,3.5%(36
of 1024) of recurrences with asexual P. falciparum infection were
associated with patent P. falciparum gametocytemia. Gameto-
cyte data for recurrences of P. vivax infection were not available.
Hematocrit data were available for 90.7% of patients (9565 of
10,549) at enrollment and 58.9% of patients (1724 of 2925) at
the time of treatment failure. In total, 14.5% of patients (1382 of
9565) were anemic (hematocrit ,30%) at enrollment to the
studies. Of those who did not have parasitological failure, 13.5%
of patients (925 of 6869) were anemic at baseline, compared
with 4.0% of patients (192 of 4755) at the last follow-up visit
(P, .001).Thecorrespondingﬁguresatbaselineandatthetime
of recurrence were 14.2% of patients (169 of 1189) versus 11.3%
of patients (78 of 692) for those who experienced treatment
failure due to P. falciparum (P 5 .1) and 18.7% of patients (296
of 1586) versus 7.2% of patients (78 of 1091) for those who
experienced treatment failure due to P. vivax (P , .001). Pa-
tients who had recurrent P. falciparum monoinfection, P. vivax
monoinfection, or mixed infection were anemic at the time of
failure in 11.9% (75 of 633), 7.3% (75 of 1032), and 5.1% (3 of
59) of cases, respectively (P 5 .004 for overall difference).
Symptomatology data were available at the time of parasito-
logical failure for 68.3% of study participants (1997 of 2925).
Recurrences with P. falciparum monoinfection,P .v i v a xmon-
oinfection, andmixedinfections were associated withsymptoms
in 65.5% (537 of 820), 44.3% (495 of 1118), and 71.2% (42 of
59) of cases, respectively (P , .001 for overall difference). At the
time of recurrence, the proportion of patients who were febrile
(temperature .37.5C) or had a history of fever within the last
24 h was 51.7% (455 of 880) for those with P. falciparum
monoinfections, 33.6% (386 of 1,148) for those with P. vivax
monoinfections, and 61.4% (35 of 57) for those with mixed
infections (P , .001 for overall difference).
Of patients who had recurrent P. falciparum monoinfection,
P. vivax monoinfection, or mixed infection, 41.2% (523
of1269),30.5%(479of1570)and58.1%(50of86),respectively,
presented outside of routine weekly follow-up and there-
fore presumably of their own volition (P , .001 for overall
difference). P. vivax infection recurrences after treatment with
short, intermediate, and long half-life combinations were
symptomatic in 58.3% (158 of 271), 42.7% (230 of 539), and
40.6% (149 of 367) of cases, respectively (P , .001 for overall
difference).
Risk Factors for Recurrence of P. vivax Infection
The cumulative risk of P. vivax infection recurrence by day 63
after P. falciparum monoinfection was 29.4% (95% CI, 27.9%–
30.9%), and the risk after mixed infection was 49.3% (95% CI,
44.3%–54.5%); adjusted hazard ratio (AHR), 2.47; 95% CI,
2.15–2.85; P , .001 (Tables 2 and 3). Univariable analyses
showed a statistically signiﬁcant increase in the risk of P. vivax
infection recurrence after pure P. falciparum infection with de-
creasing age, low hematocrit (,30%), increasing loge asexual
parasite density, and presence of P. falciparum gametocytemia
(Table 2). Male patients were signiﬁcantly more likely to have
recurrent P. vivax infection after both monoinfection due to P.
falciparum and mixed infections (Tables 2 and 3; AHR, 1.27;
95% CI, 1.14–1.41; P , .001).
Effect of Antimalarial Drugs on Risk of Recurrence of P. vivax
Infection
The median times to P. vivax infection recurrence after treat-
ment with short, intermediate, and long half-life regimens were
28, 29, and 49 days, respectively (P , .001 for overall difference;
Figure 1). Treatment with slowly eliminated antimalarials was
associated with a signiﬁcant trend to decreasing risk of P. vivax
infection recurrence up to 63 days after both malaria due to
P.falciparummonoinfection and malaria due tomixedinfection
(P , .001 for trend in both cases; Figure 2). The cumulative
proportion of patients treated with a rapidly eliminated anti-
malarial who had a recurrence of P. vivax infection after pure
falciparum malaria was 53.8% (95% CI, 48.5%–59.3%),
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treated with slowly eliminated regimens (P , .001). All patients
with mixed-species infections who were treated with a rapidly
eliminated antimalarial had a recurrent infection within 49 days
of follow-up. The adjusted hazard ratios for P. vivax infection
recurrence after either P.falciparum infectionormixedinfection
for patients receiving long or intermediate half-life regimens
were 0.43 (95% CI, 0.29–0.63; P , .001) and 0.12 (95% CI,
0.08–0.18; P , .001), respectively, when compared with those
receiving rapidly eliminated antimalarials (Table 3).
The median times to P. vivax infection recurrence after ar-
tesunate-atovaquone-proguanil, artemether-lumefantrine, arte-
sunate-meﬂoquine, dihydroartemisinin-piperaquine, and
artemether-meﬂoquine treatment were 28, 29, 49, 49, and 56
days, respectively (P , .001 for overall difference). Of the ar-
temisinin combination therapies, those regimens containing
meﬂoquine or piperaquine appeared to be equally effective at
preventing P. vivax infection recurrence in both univariable and
multivariable analyses (Figure 3 and Table 3). The shorter-
acting combinations, artemether-lumefantrine and artesunate-
atovaquone-proguanil, were associated with 3.6-fold and
4.2-fold increases in risk of P. vivax infection recurrence, re-
spectively, when compared with artesunate-meﬂoquine treat-
ment (P ,.001 in both cases) (Table 3).
DISCUSSION
InalargeseriesofclinicaltrialsconductedontheThai-Myanmar
border, P. vivax infection accounted for substantially more
malaria recurrences within 63 days of treatment for falciparum
or mixed malaria than did P. falciparum infection. Because
P. vivax is more frequently associated with gametocytemia [3, 9,
11] and is more transmissible at low parasite densities [18], the
most commonly transmitted parasite after treatment for falci-
parum malaria,paradoxically,was notP.falciparum,but P.vivax.
Statistically signiﬁcant baseline risk factors for P. vivax in-
fection recurrence after acutefalciparum malariaincluded initial
mixed-species infection, male sex, younger age, higher total
asexual parasitemia, lower hematocrit, and the presence of
P. falciparum gametocytemia. Slowly eliminated antimalarial
regimens, such as those containing meﬂoquine or piperaquine,
were associated with a markedly lower risk of P. vivax infection
recurrence than were rapidly eliminated drugs.
High asexual P. falciparum parasitemia is a well-recognized
risk factor for subsequent P. falciparum recrudescence [19–23].
In the present analysis, we have shown that it also increases the
risk of P. vivax infection recurrence. One potential explanation
for this phenomenon is that higher P. falciparum density, lower
hematocrit, and younger age are proxy markers of malaria
Table 2. Baseline Risk Factors for Plasmodium vivax Recurrence, by Initial Species Isolated
Plasmodium falciparum infection Mixed P. falciparum/P. vivax infection
Variable
No. of
cases
Treatment
failure
a 95% CI P
No. of
cases
Treatment
failure,%
a 95% CI P
Age group
,5 years 802 39.4 33.7–45.6 ,.001
b 204 56.2 43.1–70.1 .6
b
5–15 years 3347 35.4 32.7–38.3 607 52.9 45.9–60.1
.15 years 5236 24.6 22.8–26.5 353 41.4 33.7–50.1
Sex
Male 5925 30.3 28.4–32.3 .03 639 53.7 47.0–60.7 .02
Female 3460 27.8 25.5–30.3 525 43.7 36.7–51.5
Hematocrit, %
,30 1252 38.6 34.4–43.1 ,.001 130 47.2 35.1–61.2 .4
>30 7318 27.9 26.3–29.6 865 50.4 44.9–56.2
Loge parasitemia
,25
th centile (1400 parasites/lL) 2454 23.3 20.7–26.2 ,.001
b 158 39.3 28.2–53.0 .005
b
25
th–50
th centile (1400–6600 parasites/lL) 2223 26.8 23.7–30.1 391 50.0 41.1–59.6
50
th –7 5
th centile (6600–35,900 parasites/lL) 2184 29.4 26.4–32.5 429 40.1 32.0–49.3
.75
th centile (.35,900 parasites/lL) 2524 36.9 33.9–40.0 186 69.4 59.5–78.8
P. falciparum gametocytemia at enrollment
No 8847 28.7 27.2–30.3 ,.001 1116 48.3 43.2–53.6 .008
Yes 437 41.4 34.4–49.2 43 69.1 48.5–87.4
Total 9385 29.4 27.9–30.9 1164 49.3 44.3–54.5
NOTE. CI, conﬁdence interval.
a Kaplan-Meier cumulative failure estimates (%) at day 63.
b Log-rank test for trend.
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P. vivax infections. If this is true, relapses due to P. vivax hyp-
nozoites acquired at or around the same time as the index
P. falciparum infection would have a greater chance of reaching
patency. Simultaneous or near simultaneous infection due to
P. falciparum and P. vivax is probably relatively common.
Mason et al [24] showed that 10.5% of patients treated for
P. vivax malaria in Bangkok subsequently had a recurrence of
P. falciparum infection within 28 days. Because P. falciparum
does not have a dormant form, and because there is no local
malaria transmission in Bangkok, these parasites are most likely
to have been acquired at the same time as the P. vivax infections.
An alternative, but potentially complimentary, hypothesis is
that high parasitemia and low hematocrit are indicators of
greater disease severity and hence of pathophysiological and
immunological derangement, a consequence of which may be
stimulation of P. vivax infection relapse and/or failure to
suppress growth of recurrent blood stage infection. This
mechanism would be equally plausible regardless of whether the
relapsing P. vivax hypnozoites had been acquired at the same
time or prior to the index P. falciparum infection. Because the
excess risk of P. vivax infection recurrence is seen even after
slowly eliminated therapies, these putative factors would either
have to be long-lasting or induce a prolonged stream rather than
a single pulse of relapsing merozoites from the liver.
Highly sensitive polymerase chain reaction–based assays
typically reveal a much higher prevalence of concurrent mixed-
species infection than does examination with light microscopy
[5, 25–28]. This suggests that a sizeable proportion of patients
with microscopically conﬁrmed P. falciparum monoinfection in
regions of co-endemicity actually have subpatent P. vivax par-
asitemia. In our study, patients presenting with falciparum ga-
metocytemia were at 1.38 times the risk of early recurrence with
P. vivax infection, compared with the risk among patients
without gametocytemia. The presence of gametocytes is more
likelyinpatientswithchronic,asymptomaticinfectionsandmay
therefore be suggestive of multiple previous exposures to both
Plasmodium species and thus a greater risk of subpatent vivax
infection at enrollment.
Our pooled meta-analysis included a large number of in-
dividuals who were treated with multiple different antimalarial
regimens. The individual trials were conducted in similar physical
environments, which helped to ensure the comparability of their
results. Nevertheless, several sources of inter-study heterogeneity
r e m a i n .S o m eo ft h e s ec o u l db ep a r t i a l l ya d d r e s s e di nm u l t i v a r i -
able models by controlling for differences in the age structure and
median parasite density of study participants. Other known and
unknown sources of heterogeneity, such as differences in dosing
schedules for individual regimens and temporal differences in
local malaria incidence, could not be controlled for. By using Cox
Table 3. Multivariable Cox Proportional Hazards Models Show-
ing the Effect of Baseline Factors and Antimalarial Drugs on Risk
of Plasmodium vivax Recurrence
Recurrence with P. vivax
AHR 95% CI P
All drugs
Drug half-life
Short (t1/2 , 1 day) 1 ..
Intermediate (t1/2 1–7 days) .43 .29–.63 ,.001
Long (t1/2 . 7 days) .12 .08–.18 ,.001
Species at enrollment
Pure P. falciparum 1 ..
Mixed P. falciparum/P. vivax 2.47 2.15–2.85 ,.001
Age, per year increase .98 .97–.98 ,.001
Sex
Female 1 ..
Male 1.27 1.14–1.41 ,.001
Hct, per percentage point increase .98 .97–.99 ,.001
Loge parasite density, per loge order 1.09 1.07–1.12 ,.001
P. falciparum gametocytemia
No 1 ..
Yes 1.38 1.14–1.69 .001
Artemisinin combination therapies
a
Artesunate 1 meﬂoquine
combinations
1 ..
DHA 1 piperaquine combinations 1.12 .79–1.58 .5
Artemether 1 meﬂoquine
combinations
.80 .42–1.51 .5
Artemether 1 lumefantrine 3.57 2.91–4.37 ,.001
Artesunate 1 atovaquone 1
proguanil
4.20 2.79–6.31 ,.001
NOTE. CI, conﬁdence interval; DHA, dihydroartemisinin; Hct, hematocrit;
AHR, adjusted hazard ratio.
a Model also includes species at enrollment, age, sex, hematocrit, loge
parasite density, and P. falciparum gametocytemia at enrollment.
Figure 1. Risk of Plasmodium vivax recurrence after Plasmodium
falciparum monoinfection or mixed P. vivax/P. falciparum malaria by week
of follow-up and antimalarial half-life.
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of speciﬁc regimens across the different studies [17].
The long-term beneﬁts of prolonged post-exposure pro-
phylaxis against recurrent parasitemia have yet to be de-
termined. With the exception of the antifolate drugs,
antimalarial compounds active against P. falciparum have ex-
cellent efﬁcacy against the blood stages of P. vivax, and thus, the
drug regimens included in this analysis should have cleared
initial subpatent P. vivax infections [29]. The risk of P. vivax
reinfection in this region is low (,5% during a 42-day period)
[13, 30]. One can therefore assume that most of the observed
P. vivax infection recurrences were relapses. Hypnozoites have
the potential to seed multiple relapses, and it is not known
whether prevention of just one of these by use of a slowly
eliminated antimalarial will reduce the total number of relapses
or simply delay the occurrence of the next relapse. If the former
is true, the total morbidity from a given vivax infection could be
reduced, and total gametocyte carriage and, hence, trans-
missibility would also be expected to decrease. A greater period
of post-exposure prophylaxis against recurrence of infectiondue
to any Plasmodium species should also facilitate fuller hemato-
logical and clinical recovery [3, 9].
These speculative beneﬁts must be weighed against potential
disadvantages. Drugs with long terminal elimination half-lives
will be present in the bloodstream at subtherapeutic concen-
trations for longer than rapidly eliminated drugs and will
Figure 2. Kaplan–Meier failure estimates for the cumulative risk of Plasmodium vivax recurrence after Plasmodium falciparum infection (A) and
following mixed P. falciparum/P. vivax infection (B) by antimalarial half-life.
Figure 3. Kaplan–Meier failure estimates for the cumulative risk of Plasmodium vivax recurrence after Plasmodium falciparum infection (A) and
following mixed P. falciparum/P. vivax infection (B) for artemisinin combination therapies. AS1MQ, artesunate plus mefloquine; DHA 1 PIP,
dihydroartemisinin plus piperaquine; AM1MQ, artemether plus mefloquine; AM1LUM, artemether plus lumefantrine; AS1AV1PG, artesunate plus
atovaquone plus proguanil.
618 d CID 2011:52 (1 March) d Douglas et altherefore provide a more powerful force for the spread of drug-
resistant parasites [12, 31, 32]. The combination of meﬂoquine
and artesunate has been used for the treatment of P. falciparum
malaria along the northwestern border of Thailand both in trials
and in routine practice since 1994. Recent studies have revealed
an increase in the prevalence of PvMDR1 gene ampliﬁcation in
local P. vivax isolates, a polymorphism associated with reduced
susceptibilitytomeﬂoquine[33].Althoughpost-hocexploratory
analyses (not presented) show that the risk of P. vivax infection
recurrence after meﬂoquine-artesunate therapy has increased
slightly with time, it is unclear whether this is due to emerging
meﬂoquine tolerance or variation in background endemicity.
In this series of clinical trials, P. vivax was the most common
cause ofparasitological failureandwas almostcertainly the most
frequently transmitted parasite after P. falciparum infection and
mixedinfection.TheriskofP.vivaxinfectionrecurrenceinthe 9
weeks after initial falciparum malaria or mixed malaria is in-
versely correlated with antimalarial half-life. Slowly eliminated
regimens should facilitate full clinical recovery and, if used on
a large scale, may reduce transmission of both P. falciparum and
P. vivax. Although additional work is required to establish the
risk and deleterious effects of P. vivax infection recurrence in
other regions, our study suggests that there is a coherent argu-
ment for the safe provision of a sterilizing course of antirelapse
therapy (currently, 14 days of primaquine) for all patients with
malaria in regions of co-endemicity.
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